Checkpoint Therapeutics, Inc.
CKPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.01 | 0.15 | -0.05 |
| FCF Yield | -24.50% | -110.88% | -127.47% | -11.13% |
| EV / EBITDA | -2.14 | -0.73 | -0.61 | -3.22 |
| Quality | ||||
| ROIC | 444.94% | 399.69% | 299.40% | -190.69% |
| Gross Margin | 100.00% | -42,197.09% | -25,850.52% | -17,979.48% |
| Cash Conversion Ratio | 0.55 | 0.92 | 0.92 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | -40.23% | -27.29% | -43.58% | 644,630.57% |
| Free Cash Flow Growth | 34.65% | 17.31% | -118.79% | -58.94% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 0.09 | 0.22 | 0.97 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -55.04 | 54.27 | -98.42 |